In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to bounce back from yesterday’s drop. At the time of writing the benchmark index is up 0.9% to 6,658.2 points.
Four shares that are climbing more than most today are listed below. Here’s why they are storming higher:
A2 Milk Company Ltd (ASX: A2M)
The a2 Milk share price is up a further 3.5% to $11.15. Investors have been buying the infant formula company’s shares this week after a horror showing a week earlier. It appears as though some investors believe the sell off on Friday has dragged its shares down to an attractive level. The a2 Milk share price was sold off after it downgraded its guidance for FY 2021.
Air New Zealand Limited (ASX: AIZ)
The Air New Zealand share price is up 3.5% to $1.64. This follows the release of an update on its operations this morning. Air New Zealand revealed that it carried a total of 690,000 passengers in November. While this is roughly half what it carried a year earlier, it is an improvement from earlier in the financial year.
Mesoblast limited (ASX: MSB)
The Mesoblast share price is up 6% to $2.30 despite there being no news out of the biotech company. However, with its shares halving in value over the last few trading days, some investors may believe they have been oversold. Alternatively, as Mesoblast is one of the most shorted shares on the ASX, the buying could be from short sellers closing positions.
Recce Pharmaceuticals Ltd (ASX: RCE)
The Recce share price has pushed 4% higher to $1.12. The catalyst for this was the release of results from its international SARS-CoV-2 (COVID-19) in-vivo studies. The results demonstrate positive activity of RECCE 327 (R327) and RECCE 529 (R529) against COVID-19 in Syrian golden hamsters. Management believes this hamster study is the first indication of the potential for nasal administration of its anti-infective compounds, specifically when used against viruses.
This Tiny ASX Stock Could Be the Next Afterpay
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting…
Because ‘Doc’ Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.
Doc and his team have published a detailed report on this tiny ASX stock. Find out how you can access what could be the NEXT Afterpay today!
See how you can find out the name of this stock
Returns as of 6th October 2020
More reading
- Air New Zealand (ASX:AIZ) share price rises despite falling air traffic
- Recce (ASX:RCE) share price charges higher on COVID-19 update
- Why a2 Milk and these ASX shares have been smashed in 2020
- 7 top ASX biomedical shares in 2020
- Leading brokers name 3 ASX shares to sell today
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post Why a2 Milk, Air New Zealand, Mesoblast, & Recce shares are storming higher appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/37FqHEm
Leave a Reply